RxDoctor Payments Data

Francis Burt, MD

Cardiovascular Disease · Bethlehem, PANPI 1619127362

Payments from drug & device makers

$8,822in general payments, 2019–2025

Across 49 payments — averaging $180.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$7K
  • Edwards Lifesciences$701
  • United Therapeutics Corporation$360
  • Medtronic$101
  • E.r. Squibb & Sons, L.L.C.$94
  • Insulet Corporation$36
  • plus $51 from 3 others

What the payments were for

  • Speaking & faculty fees$6,35572%
  • Travel & lodging$110%
  • Food & beverage$2,45628%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,822 in reported general payments places this provider in the 75th percentile of 1,250 cardiovascular disease providers in Pennsylvania.

See all cardiovascular disease providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$224,867
Medicare patients
1,995
Services billed
4,141

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban635$609,234
VyndamaxTafamidis12$268,202
XareltoRivaroxaban233$259,317
EntrestoSacubitril/Valsartan48$51,948
Repatha SureclickEvolocumab11$11,478
JardianceEmpagliflozin11$9,751
Dabigatran EtexilateDabigatran Etexilate Mesylate23$9,401
Metoprolol Succinate478$8,409
Flecainide Acetate170$8,217
Bisoprolol Fumarate177$6,348
Atorvastatin Calcium539$5,789
Torsemide254$4,001
Diltiazem 24hr Er (Cd)Diltiazem Hcl99$3,083
Candesartan Cilexetil20$2,898
Potassium Chloride139$2,812

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$7,479$259,317233 claims
NovartisEntresto$17$51,94848 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,250 cardiovascular disease providers in Pennsylvania.

Other cardiovascular disease in Bethlehem

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →